Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
نویسندگان
چکیده
منابع مشابه
Disease-modifying therapies in relapsing–remitting multiple sclerosis
CLINICAL QUESTION What is the best current disease-modifying therapy for relapsing-remitting multiple sclerosis? RESULTS The evidence shows that the most effective disease-modifying therapy for delaying short- to medium-term disability progression, prevention of relapses, reducing the area and activity of lesions on magnetic resonance imaging, with the least side effects, is high-dose, high-f...
متن کاملEfficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison.
The treatment of relapsing-remitting multiple sclerosis (RRMS) has become more effective over the last decade with the advent of the currently available disease-modifying therapies (DMTs). Pivotal clinical studies differ in many characteristics, such that cross-comparisons of relative risk reductions are of limited value and can be misleading. Our objective was to compare the clinical efficacy ...
متن کاملEffects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis
Background: Progressive brain atrophy is a major feature of multiple sclerosis (MS) pathology and is actually considered a major determinant of the progressive accumulation of physical and cognitive disability in MS patients. Although brain atrophy may have different pathological substrates, several lines of evidence suggest that in disease modifying drug (DMD)-treated MS patients, the higher i...
متن کاملcost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in iran.
background: disease-modifying drugs (dmds) are a significant expenditure for treating multiple sclerosis (ms). however, there is limited report on assessment of the cost-utility of dmds compared with symptom management in the presence of long-term data. this study aimed to assess the lifetime cost-utility from the iranian healthcare perspectives of 4dmds relative to symptom management alone in ...
متن کاملDisease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
With the development of effective therapies for multiple sclerosis (MS), therapeutic nihilism, which was so prevalent just 10 years ago, has given way to exuberance and optimism. The current mood is understandable because MS is such a devastating disease. Within 10 years of symptom onset, 50% of patients with MS are unable to carry out household and employment responsibilities; within 15 to 20 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacy
سال: 2020
ISSN: 2226-4787
DOI: 10.3390/pharmacy8020061